secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2023-04-27T23:59:59+00:00
Accession:  0000950170-23-015343
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Soticlestat long-term OLE data shows sustained seizure reduction in Dravet and LGS
--------------------------------------------------------------------------------

- ENDYMION 1 interim analysis: soticlestat generally safe and well tolerated over ~2 years; 78% tolerated 300 mg BID.
- Dravet patients: median convulsive seizure reduction -33.7% (wk1-12), -47.8% (wk49-60), -58.2% (wk97-108).
- LGS patients: median drop seizure reduction -29.3% (wk1-12), -14.1% (wk49-60), -36.6% (wk97-108).
- Post-hoc ELEKTRA analysis: soticlestat showed numerically superior reduction vs placebo across most seizure types.
- Ovid maintains significant financial interest in soticlestat (milestones and royalties from Takeda).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000095017023015343/0000950170-23-015343-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000095017023015343/ovid-20230427.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-015343

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer